CL2A-SN-38 DCA 1279680-68-0(free base) 是一种药物-接头偶联物，由有效的 DNA 拓扑异构酶 I 抑制剂 SN-38 和接头 CL2A 组成，用于制造抗体药物偶联物 (ADC)。CL2A-SN-38 由有效的 DNA 拓扑异构酶组成I 抑制剂 SN-38 和接头 CL2A 以制造抗体药物偶联物 (ADC)。 CL2A-SN-38 对一系列人类实体瘤类型提供显着和特异性的抗肿瘤作用。 CL2A 是一种不可切割的复杂 PEG8 和含有三唑的 PABC-肽-mc 接头。 CL2A 可通过 pH 敏感性裂解，产生旁观者效应，并通过二硫键在半胱氨酸残基处结合抗体。

CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .

T17731L

C77H101Cl4N11O26

1738.49

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years